Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription 30.09.2019 1 Am J Pathol 1 Am J Respir Crit Care Med 1 Ann Oncol 1 Ann Surg Oncol 4 Ann Thorac Surg 5 Anticancer Res 4 Clin Cancer Res 2 Eur Respir J 3 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 Lancet Respir Med 2 Lung Cancer 1 N Engl J Med 1 Oncogene 3 Oncol Rep 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Pathol

1. PHAM HHN, Futakuchi M, Bychkov A, Furukawa T, et al
   Detection of lung cancer lymph node metastases from whole-slide histopathological images using a two-step deep learning approach.
   Am J Pathol. 2019 Sep 18. pii: S0002-9440(19)30718.
   PubMed     Text format     Abstract available
   
   

   
   Am J Respir Crit Care Med

2. WATANABE H, Powell CA
   Sequencing Lung Cancer's Sequence.
   Am J Respir Crit Care Med. 2019;200:657-659.
   PubMed     Text format    
   
   

   
   Ann Oncol

3. YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
   Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell
   Ann Oncol. 2019 Sep 25. pii: 5573754. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

4. ZENG Y, Mayne N, Yang CJ, Liang W, et al
   ASO Author Reflections: TNM 8th Edition: Stage I Non-small Cell Lung Cancer-Free from Recurrence and Adjuvant Therapy? How to Predict?
   Ann Surg Oncol. 2019 Sep 25. pii: 10.1245/s10434-019-07856.
   PubMed     Text format    
   
   

   
   Ann Thorac Surg

5. MORI M, Takenaka M, Ichiki Y, Tanaka F, et al
   Simple Carinal Cartilage Suture for High-Caliber Mismatch in Right Upper Lobe Sleeve Lobectomy.
   Ann Thorac Surg. 2019;108:e61-e63.
   PubMed     Text format     Abstract available
   
   
6. CARPENTER AJ, Novick WM, Sade RM
   The Devoted Grandma: Is a Social Indication for TAVR Acceptable?
   Ann Thorac Surg. 2019;108:5-10.
   PubMed     Text format    
   
   
7. AYDIN Y, Ogul H, Bayraktutan U, Ulas AB, et al
   Miliary Lung Metastases in Echinococcus Multilocularis Infection.
   Ann Thorac Surg. 2019;108:e47.
   PubMed     Text format    
   
   
8. MITCHELL KG, Negrao MV, Parra ER, Li J, et al
   Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.
   Ann Thorac Surg. 2019 Sep 21. pii: S0003-4975(19)31416.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

9. KIYUNA T, Tome Y, Miyake K, Murakami T, et al
   Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
   Anticancer Res. 2019;39:4775-4779.
   PubMed     Text format     Abstract available
   
   
10. HARADA D, Takata K, Mori S, Kozuki T, et al
    Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
    Anticancer Res. 2019;39:4987-4993.
    PubMed     Text format     Abstract available
    
    
11. KASMANN L, Taugner J, Eze C, Roengvoraphoj O, et al
    Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
    Anticancer Res. 2019;39:5077-5081.
    PubMed     Text format     Abstract available
    
    
12. ANDO K, Hamada K, Watanabe M, Ohkuma R, et al
    Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:5195-5201.
    PubMed     Text format     Abstract available
    
    
13. FONTANA V, Pistillo MP, Vigani A, Canessa PA, et al
    Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Anticancer Res. 2019;39:5219-5223.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

14. JEONG Y, Hellyer JA, Stehr H, Hoang NT, et al
    Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1237.
    PubMed     Text format     Abstract available
    
    
15. ROTOW JK, Gui P, Wu W, Raymond VM, et al
    Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1667.
    PubMed     Text format     Abstract available
    
    
16. GERBER DE, Infante JR, Gordon MS, Goldberg SB, et al
    Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-18-3965.
    PubMed     Text format     Abstract available
    
    
17. MANSFIELD AS, Zauderer MG
    Nivo-lution in Mesothelioma.
    Clin Cancer Res. 2019;25:5438-5440.
    PubMed     Text format     Abstract available
    
    

    
    Eur Respir J

18. OBERT M
    Are estimations of radiomic image markers dispensable due to recent deep learning findings?
    Eur Respir J. 2019;54.
    PubMed     Text format    
    
    
19. SOLTANI A, Mahmood MQ, Reid DW, Walters EH, et al
    Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation.
    Eur Respir J. 2019;54.
    PubMed     Text format    
    
    

    
    J Cancer Res Clin Oncol

20. WANG A, Komiya T
    Brain metastasis as exclusion criteria in clinical trials involving extensive-stage small cell lung cancer.
    J Cancer Res Clin Oncol. 2019 Sep 23. pii: 10.1007/s00432-019-03034.
    PubMed     Text format     Abstract available
    
    
21. LIU L, Song X, Li X, Xue L, et al
    A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer.
    J Cancer Res Clin Oncol. 2019 Sep 24. pii: 10.1007/s00432-019-03032.
    PubMed     Text format     Abstract available
    
    
22. ZHOU C, Che G, Zheng X, Qiu J, et al
    Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2019 Sep 20. pii: 10.1007/s00432-019-03025.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

23. DIRKSEN U, Brennan B, Le Deley MC, Cozic N, et al
    High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
    J Clin Oncol. 2019 Sep 25:JCO1900915. doi: 10.1200/JCO.19.00915.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Cardiovasc Surg

24. GROTH SS, Ripley RT, Burt BM
    A thinner peel to peel: Pleural thickness is prognostic in mesothelioma.
    J Thorac Cardiovasc Surg. 2019;157:414-415.
    PubMed     Text format    
    
    
25. SEMENKOVICH TR, Puri V
    Surgery versus stereotactic body radiation therapy: Definitive evidence is still elusive.
    J Thorac Cardiovasc Surg. 2019;157:374-375.
    PubMed     Text format    
    
    

    
    J Thorac Oncol

26. HSU CC, Liao BC, Liao WY, Markovets A, et al
    Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.
    J Thorac Oncol. 2019 Sep 23. pii: S1556-0864(19)33307.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Respir Med

27. VENKATESAN P
    IASLC 2019 World Conference on Lung Cancer.
    Lancet Respir Med. 2019 Sep 20. pii: S2213-2600(19)30330.
    PubMed     Text format    
    
    

    
    Lung Cancer

28. KADOURI L, Rottenberg Y, Zick A, Hamburger T, et al
    Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Lung Cancer. 2019;137:48-51.
    PubMed     Text format     Abstract available
    
    
29. TERAMOTO K, Igarashi T, Kataoka Y, Ishida M, et al
    Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Lung Cancer. 2019;137:56-63.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

30. GUINEY TE, Lopes MS, Kalra MK, Mooradian MJ, et al
    Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain.
    N Engl J Med. 2019;381:1268-1277.
    PubMed     Text format    
    
    

    
    Oncogene

31. SHIN SB, Jang HR, Xu R, Won JY, et al
    Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer.
    Oncogene. 2019 Sep 23. pii: 10.1038/s41388-019-1023.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

32. NAN Y
    Lung carcinoma therapy using epidermal growth factor receptortargeted lipid polymeric nanoparticles coloaded with cisplatin and doxorubicin.
    Oncol Rep. 2019 Sep 18. doi: 10.3892/or.2019.7323.
    PubMed     Text format     Abstract available
    
    
33. WANG J, Hu ZG, Li D, Xu JX, et al
    Gene expression and prognosis of insulinlike growth factorbinding protein family members in nonsmall cell lung cancer.
    Oncol Rep. 2019 Sep 16. doi: 10.3892/or.2019.7314.
    PubMed     Text format     Abstract available
    
    
34. WEI W, Zhao X, Zhu J, Zhang L, et al
    lncRNAu50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.
    Oncol Rep. 2019 Sep 5. doi: 10.3892/or.2019.7302.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

35. HU HP, Chan H, Ujiie H, Bernards N, et al
    Nanoparticle-based CT visualization of pulmonary vasculature for minimally-invasive thoracic surgery planning.
    PLoS One. 2019;14:e0209501.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: